PET Imaging of Tau Deposition in the Aging Human Brain

Neuron

Volumn 89, Issue 5, 2016, Pages 971-982

  Schöll, Michael ^a,b   Lockhart, Samuel N ^a   Schonhaut, Daniel R ^c   O'Neil, James P ^d   Janabi, Mustafa ^d   Ossenkoppele, Rik ^a,c,e   Baker, Suzanne L ^d   Vogel, Jacob W ^a   Faria, Jamie ^d   Schwimmer, Henry D ^a   Rabinovici, Gil D ^a,c,d   Jagust, William J ^a,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d LAWRENCE BERKELEY NATIONAL LABORATORY   (United States)

^e VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Aging; Amyloid; Memory; PET; Tau

Indexed keywords

AMYLOID BETA PROTEIN; FLORTAUCIPIR F 18; TAU PROTEIN; 2-(4'-(METHYLAMINO)PHENYL)-6-HYDROXYBENZOTHIAZOLE; ANILINE DERIVATIVE; APOLIPOPROTEIN E; ETHYLENE GLYCOL DERIVATIVE; FLORBETAPIR; THIAZOLE DERIVATIVE;

ADULT; AGED; AGING; ARTICLE; CASE REPORT; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG RETENTION; DRUG UPTAKE; EPISODIC MEMORY; FEMALE; HUMAN; MALE; MENTAL PERFORMANCE; NEUROIMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN LOCALIZATION; AGE; ALZHEIMER DISEASE; BRAIN; COGNITION DISORDERS; COMPLICATION; DIAGNOSTIC IMAGING; GENETICS; METABOLISM; PATHOLOGY; PSYCHOLOGICAL RATING SCALE; VERY ELDERLY; YOUNG ADULT;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; AGING; ALZHEIMER DISEASE; ANILINE COMPOUNDS; APOLIPOPROTEINS E; BRAIN; COGNITION DISORDERS; ETHYLENE GLYCOLS; FEMALE; HUMANS; MALE; POSITRON-EMISSION TOMOGRAPHY; PSYCHIATRIC STATUS RATING SCALES; TAU PROTEINS; THIAZOLES; YOUNG ADULT;

EID: 84960453922     PISSN: 08966273     EISSN: 10974199     Source Type: Journal    
DOI: 10.1016/j.neuron.2016.01.028     Document Type: Article

References (57)

1. Alafuzoff I., Arzberger T., Al-Sarraj S., Bodi I., Bogdanovic N., Braak H., Bugiani O., Del-Tredici K., Ferrer I., Gelpi E., et al. Staging of neurofibrillary pathology in Alzheimer's disease: a study of the BrainNet Europe Consortium. Brain Pathol. 2008, 18:484-496.
2. Arriagada P.V., Growdon J.H., Hedley-Whyte E.T., Hyman B.T. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology 1992, 42:631-639.
3. Bennett D.A., Schneider J.A., Arvanitakis Z., Kelly J.F., Aggarwal N.T., Shah R.C., Wilson R.S. Neuropathology of older persons without cognitive impairment from two community-based studies. Neurology 2006, 66:1837-1844.
4. Bennett D.A., Wilson R.S., Boyle P.A., Buchman A.S., Schneider J.A. Relation of neuropathology to cognition in persons without cognitive impairment. Ann. Neurol. 2012, 72:599-609.
5. Bouras C., Hof P.R., Giannakopoulos P., Michel J.P., Morrison J.H. Regional distribution of neurofibrillary tangles and senile plaques in the cerebral cortex of elderly patients: a quantitative evaluation of a one-year autopsy population from a geriatric hospital. Cereb. Cortex 1994, 4:138-150.
6. Braak H., Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991, 82:239-259.
7. Braak H., Braak E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol. Aging 1997, 18:351-357.
8. Braak H., Braak E., Bohl J., Reintjes R. Age, neurofibrillary changes, A beta-amyloid and the onset of Alzheimer's disease. Neurosci. Lett. 1996, 210:87-90.
9. Braak H., Alafuzoff I., Arzberger T., Kretzschmar H., Del Tredici K. Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol. 2006, 112:389-404.
10. Braak H., Thal D.R., Ghebremedhin E., Del Tredici K. Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. J. Neuropathol. Exp. Neurol. 2011, 70:960-969.
11. Chien D.T., Bahri S., Szardenings A.K., Walsh J.C., Mu F., Su M.-Y., Shankle W.R., Elizarov A., Kolb H.C. Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. J. Alzheimers Dis. 2013, 34:457-468.
12. Crary J.F., Trojanowski J.Q., Schneider J.A., Abisambra J.F., Abner E.L., Alafuzoff I., Arnold S.E., Attems J., Beach T.G., Bigio E.H., et al. Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol. 2014, 128:755-766.
13. Davis D.G., Schmitt F.A., Wekstein D.R., Markesbery W.R. Alzheimer neuropathologic alterations in aged cognitively normal subjects. J. Neuropathol. Exp. Neurol. 1999, 58:376-388.
14. Deary I.J., Corley J., Gow A.J., Harris S.E., Houlihan L.M., Marioni R.E., Penke L., Rafnsson S.B., Starr J.M. Age-associated cognitive decline. Br. Med. Bull. 2009, 92:135-152.
15. Duyckaerts C., Braak H., Brion J.P., Buée L., Del Tredici K., Goedert M., Halliday G., Neumann M., Spillantini M.G., Tolnay M., Uchihara T. PART is part of Alzheimer disease. Acta Neuropathol. 2015, 129:749-756.
16. Elman J.A., Oh H., Madison C.M., Baker S.L., Vogel J.W., Marks S.M., Crowley S., O'Neil J.P., Jagust W.J. Neural compensation in older people with brain amyloid-β deposition. Nat. Neurosci. 2014, 17:1316-1318.
17. Fagan A.M., Roe C.M., Xiong C., Mintun M.A., Morris J.C., Holtzman D.M. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch. Neurol. 2007, 64:343-349.
18. Fornicola W., Pelcovits A., Li B.-X., Heath J., Perry G., Castellani R.J. Alzheimer Disease Pathology in Middle Age Reveals a Spatial-Temporal Disconnect Between Amyloid-β and Phosphorylated Tau. Open Neurol. J. 2014, 8:22-26.
19. Fox L.M., William C.M., Adamowicz D.H., Pitstick R., Carlson G.A., Spires-Jones T.L., Hyman B.T. Soluble tau species, not neurofibrillary aggregates, disrupt neural system integration in a tau transgenic model. J. Neuropathol. Exp. Neurol. 2011, 70:588-595.
20. Ghoshal N., García-Sierra F., Wuu J., Leurgans S., Bennett D.A., Berry R.W., Binder L.I. Tau conformational changes correspond to impairments of episodic memory in mild cognitive impairment and Alzheimer's disease. Exp. Neurol. 2002, 177:475-493.
21. Guillozet A.L., Weintraub S., Mash D.C., Mesulam M.-M. Neurofibrillary tangles, amyloid, and memory in aging and mild cognitive impairment. Arch. Neurol. 2003, 60:729-736.
22. Hoover B.R., Reed M.N., Su J., Penrod R.D., Kotilinek L.A., Grant M.K., Pitstick R., Carlson G.A., Lanier L.M., Yuan L.-L., et al. Tau mislocalization to dendritic spines mediates synaptic dysfunction independently of neurodegeneration. Neuron 2010, 68:1067-1081.
23. Hyman B.T., Phelps C.H., Beach T.G., Bigio E.H., Cairns N.J., Carrillo M.C., Dickson D.W., Duyckaerts C., Frosch M.P., Masliah E., et al. National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement. 2012, 8:1-13.
24. Ihaka R., Gentleman R. R: a laokaynguage for data analysis and graphics. J. Comput. Graph. Stat. 1996, 5:299-314.
25. Jack C.R., Knopman D.S., Jagust W.J., Petersen R.C., Weiner M.W., Aisen P.S., Shaw L.M., Vemuri P., Wiste H.J., Weigand S.D., et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013, 12:207-216.
26. Jellinger K.A., Alafuzoff I., Attems J., Beach T.G., Cairns N.J., Crary J.F., Dickson D.W., Hof P.R., Hyman B.T., Jack C.R., et al. PART, a distinct tauopathy, different from classical sporadic Alzheimer disease. Acta Neuropathol. 2015, 129:757-762.
27. Johnson K.A., Schultz A., Betensky R.A., Becker J.A., Sepulcre J., Rentz D., Mormino E., Chhatwal J., Amariglio R., Papp K., et al. Tau PET imaging in aging and early Alzheimer's disease. Ann. Neurol. 2016, 79:110-119.
28. Landau S.M., Mintun M.A., Joshi A.D., Koeppe R.A., Petersen R.C., Aisen P.S., Weiner M.W., Jagust W.J. Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Ann. Neurol. 2012, 72:578-586. Alzheimer's Disease Neuroimaging Initiative.
29. Liu L., Drouet V., Wu J.W., Witter M.P., Small S.A., Clelland C., Duff K. Trans-synaptic spread of tau pathology in vivo. PLoS ONE 2012, 7:e31302.
30. Logan J., Fowler J.S., Volkow N.D., Wang G.J., Ding Y.S., Alexoff D.L. Distribution volume ratios without blood sampling from graphical analysis of PET data. J. Cereb. Blood Flow Metab. 1996, 16:834-840.
31. Marquie M., Normandin M.D., Vanderburg C.R., Costantino I., Bien E.A., Rycyna L.G., Klunk W.E., Mathis C.A., Ikonomovic M.D., Debnath M.L., et al. Validating novel tau PET tracer [F-18]-AV-1451 (T807) on postmortem brain tissue. Ann. Neurol. 2015, 78:787-800.
32. Mathis C.A., Wang Y., Holt D.P., Huang G.F., Debnath M.L., Klunk W.E. Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. J. Med. Chem. 2003, 46:2740-2754.
33. McKhann G.M., Knopman D.S., Chertkow H., Hyman B.T., Jack C.R., Kawas C.H., Klunk W.E., Koroshetz W.J., Manly J.J., Mayeux R., et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011, 7:263-269.
34. Menkes-Caspi N., Yamin H.G., Kellner V., Spires-Jones T.L., Cohen D., Stern E.A. Pathological tau disrupts ongoing network activity. Neuron 2015, 85:959-966.
35. Mitchell T.W., Mufson E.J., Schneider J.A., Cochran E.J., Nissanov J., Han L.-Y., Bienias J.L., Lee V.M.Y., Trojanowski J.Q., Bennett D.A., Arnold S.E. Parahippocampal tau pathology in healthy aging, mild cognitive impairment, and early Alzheimer's disease. Ann. Neurol. 2002, 51:182-189.
36. Mormino E.C., Kluth J.T., Madison C.M., Rabinovici G.D., Baker S.L., Miller B.L., Koeppe R.A., Mathis C.A., Weiner M.W., Jagust W.J. Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. Brain 2009, 132:1310-1323. Alzheimer's Disease Neuroimaging Initiative.
37. Mormino E.C., Smiljic A., Hayenga A.O., Onami S.H., Greicius M.D., Rabinovici G.D., Janabi M., Baker S.L., Yen I.V., Madison C.M., et al. Relationships between β-amyloid and functional connectivity in different components of the default mode network in aging. Cereb. Cortex 2011, 21:2399-2407.
38. Mormino E.C., Brandel M.G., Madison C.M., Rabinovici G.D., Marks S., Baker S.L., Jagust W.J. Not quite PIB-positive, not quite PIB-negative: slight PIB elevations in elderly normal control subjects are biologically relevant. Neuroimage 2012, 59:1152-1160.
39. Murray M.E., Graff-Radford N.R., Ross O.A., Petersen R.C., Duara R., Dickson D.W. Neuropathologically defined subtypes of Alzheimer's disease with distinct clinical characteristics: a retrospective study. Lancet Neurol. 2011, 10:785-796.
40. Nelson P.T., Alafuzoff I., Bigio E.H., Bouras C., Braak H., Cairns N.J., Castellani R.J., Crain B.J., Davies P., Del Tredici K., et al. Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J. Neuropathol. Exp. Neurol. 2012, 71:362-381.
41. Ossenkoppele R., Cohn-Sheehy B.I., La Joie R., Vogel J.W., Möller C., Lehmann M., van Berckel B.N.M., Seeley W.W., Pijnenburg Y.A., Gorno-Tempini M.L., et al. Atrophy patterns in early clinical stages across distinct phenotypes of Alzheimer's disease. Hum. Brain Mapp. 2015, 36:4421-4437.
42. Ossenkoppele R., Pijnenburg Y.A.L., Perry D.C., Cohn-Sheehy B.I., Scheltens N.M.E., Vogel J.W., Kramer J.H., van der Vlies A.E., Joie R.L., Rosen H.J., et al. The behavioural/dysexecutive variant of Alzheimer's disease: clinical, neuroimaging and pathological features. Brain 2015, 138:2732-2749.
43. Ossenkoppele R., Schonhaut D.R., Baker S.L., O'Neil J.P., Janabi M., Ghosh P.M., Santos M., Miller Z.A., Bettcher B.M., Gorno-Tempini M.L., et al. Tau, amyloid, and hypometabolism in a patient with posterior cortical atrophy. Ann. Neurol. 2015, 77:338-342.
44. Price J.L., Morris J.C. Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. Ann. Neurol. 1999, 45:358-368.
45. Price J.C., Klunk W.E., Lopresti B.J., Lu X., Hoge J.A., Ziolko S.K., Holt D.P., Meltzer C.C., DeKosky S.T., Mathis C.A. Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B. J. Cereb. Blood Flow Metab. 2005, 25:1528-1547.
46. Rolstad S., Berg A.I., Bjerke M., Johansson B., Zetterberg H., Wallin A. Cerebrospinal fluid biomarkers mirror rate of cognitive decline. J. Alzheimers Dis. 2013, 34:949-956.
47. Rousset O.G., Ma Y., Evans A.C. Correction for partial volume effects in PET: principle and validation. J. Nucl. Med. 1998, 39:904-911.
48. Serrano-Pozo A., Frosch M.P., Masliah E., Hyman B.T. Neuropathological alterations in Alzheimer disease. Cold Spring Harb. Perspect. Med. 2011, 1:a006189.
49. Sjögren M., Vanderstichele H., Agren H., Zachrisson O., Edsbagge M., Wikkelsø C., Skoog I., Wallin A., Wahlund L.-O., Marcusson J., et al. Tau and Abeta42 in cerebrospinal fluid from healthy adults 21-93 years of age: establishment of reference values. Clin. Chem. 2001, 47:1776-1781.
50. Small S.A., Duff K. Linking Abeta and tau in late-onset Alzheimer's disease: a dual pathway hypothesis. Neuron 2008, 60:534-542.
51. Spires-Jones T.L., Hyman B.T. The intersection of amyloid beta and tau at synapses in Alzheimer's disease. Neuron 2014, 82:756-771.
52. Tomlinson B.E., Blessed G., Roth M. Observations on the brains of non-demented old people. J. Neurol. Sci. 1968, 7:331-356.
53. Tong J., Meyer J.H., Furukawa Y., Boileau I., Chang L.-J., Wilson A.A., Houle S., Kish S.J. Distribution of monoamine oxidase proteins in human brain: implications for brain imaging studies. J. Cereb. Blood Flow Metab. 2013, 33:863-871.
54. Tromp D., Dufour A., Lithfous S., Pebayle T., Després O. Episodic memory in normal aging and Alzheimer disease: Insights from imaging and behavioral studies. Ageing Res. Rev. 2015, 24(Pt B):232-262.
55. van Rossum I.A., Visser P.J., Knol D.L., van der Flier W.M., Teunissen C.E., Barkhof F., Blankenstein M.A., Scheltens P. Injury markers but not amyloid markers are associated with rapid progression from mild cognitive impairment to dementia in Alzheimer's disease. J. Alzheimers Dis. 2012, 29:319-327.
56. Villemagne V.L., Burnham S., Bourgeat P., Brown B., Ellis K.A., Salvado O., Szoeke C., Macaulay S.L., Martins R., Maruff P., et al. Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol. 2013, 12:357-367. Australian Imaging Biomarkers and Lifestyle (AIBL) Research Group.
57. Xia C.-F., Arteaga J., Chen G., Gangadharmath U., Gomez L.F., Kasi D., Lam C., Liang Q., Liu C., Mocharla V.P., et al. [(18)F]T807, a novel tau positron emission tomography imaging agent for Alzheimer's disease. Alzheimers Dement. 2013, 9:666-676.